Published in Br J Cancer on June 07, 2011
microRNA-101 is a potent inhibitor of autophagy. EMBO J (2011) 2.00
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One (2012) 1.67
Regulation of microRNA expression and function by nuclear receptor signaling. Cell Biosci (2011) 1.12
MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. Autophagy (2012) 1.10
MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Mol Cancer (2012) 1.08
Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle (2015) 1.05
Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene (2012) 1.05
Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle (2014) 0.98
Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity. Nat Cell Biol (2015) 0.95
Targetome profiling, pathway analysis and genetic association study implicate miR-202 in lymphomagenesis. Cancer Epidemiol Biomarkers Prev (2013) 0.92
LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. Cancer Res (2013) 0.92
A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res (2014) 0.91
miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett (2013) 0.91
Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. PLoS One (2013) 0.90
LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget (2017) 0.89
The altered expression profile of microRNAs in cardiopulmonary bypass canine models and the effects of mir-499 on myocardial ischemic reperfusion injury. J Transl Med (2013) 0.89
miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) (2015) 0.89
Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res (2012) 0.88
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int (2012) 0.86
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. Am J Cancer Res (2015) 0.86
MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation. Oncotarget (2015) 0.86
Targeting CSC-related miRNAs for cancer therapy by natural agents. Curr Drug Targets (2012) 0.83
Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation. BMC Cancer (2015) 0.82
Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol (2014) 0.82
General hallmarks of microRNAs in brain evolution and development. RNA Biol (2015) 0.81
TNF-α and IGF1 modify the microRNA signature in skeletal muscle cell differentiation. Cell Commun Signal (2015) 0.81
Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells. Oncotarget (2015) 0.81
Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression. Oncogenesis (2012) 0.81
microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol (2015) 0.80
Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin (2011) 0.80
Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol (2016) 0.79
Differential expression of microRNAs as predictors of glioblastoma phenotypes. BMC Bioinformatics (2014) 0.79
MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clin Epigenetics (2015) 0.78
Cell survival signaling in neuroblastoma. Anticancer Agents Med Chem (2013) 0.78
A cell-based high-throughput screen addressing 3'UTR-dependent regulation of the MYCN gene. Mol Biotechnol (2014) 0.77
The RNA-binding protein LIN28B regulates developmental timing in the mammalian cochlea. Proc Natl Acad Sci U S A (2015) 0.77
Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. Oncotarget (2016) 0.77
N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics. Cell Death Discov (2016) 0.76
Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives. Int J Mol Sci (2012) 0.76
Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation. Mol Oncol (2015) 0.76
Cell Proliferation in Neuroblastoma. Cancers (Basel) (2016) 0.75
Co-expression Pattern Analysis of miR-17-92 Target Genes in Chronic Myelogenous Leukemia. Front Genet (2016) 0.75
Determinants of orofacial clefting II: Effects of 5-Aza-2'-deoxycytidine on gene methylation during development of the first branchial arch. Reprod Toxicol (2016) 0.75
CASC2c as an unfavorable prognosis factor interacts with miR-101 to mediate astrocytoma tumorigenesis. Cell Death Dis (2017) 0.75
Insights into inner ear-specific gene regulation: Epigenetics and non-coding RNAs in inner ear development and regeneration. Semin Cell Dev Biol (2016) 0.75
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Human MicroRNA targets. PLoS Biol (2004) 34.51
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Specificity of microRNA target selection in translational repression. Genes Dev (2004) 21.14
Neuroblastoma. Lancet (2007) 10.61
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev (2007) 10.15
A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol (2006) 10.14
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
Recent advances in neuroblastoma. N Engl J Med (2010) 7.86
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
The let-7 family of microRNAs. Trends Cell Biol (2008) 6.24
The miR-34 family in cancer and apoptosis. Cell Death Differ (2009) 5.92
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev (2009) 4.41
On the road to reading the RNA-interference code. Nature (2009) 4.33
MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res (2009) 3.83
Myc pathways provoking cell suicide and cancer. Oncogene (2003) 3.49
Human N-myc is closely related in organization and nucleotide sequence to c-myc. Nature (1986) 3.40
The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol (2006) 3.31
MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res (2008) 2.90
The MYCN oncogene is a direct target of miR-34a. Oncogene (2008) 2.80
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev (1992) 2.54
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer (2010) 2.08
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res (2008) 2.03
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol (2000) 2.02
MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res (2010) 2.00
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One (2010) 1.94
MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer (2010) 1.87
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol (2008) 1.64
MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A (2010) 1.49
MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol (2011) 1.47
The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res (2010) 1.41
Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol (2010) 1.39
Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.38
Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer (2010) 1.32
Of Myc and Mnt. J Cell Sci (2006) 1.31
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res (2010) 1.29
The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res (2006) 1.28
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A (2007) 1.26
MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer (2011) 1.25
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol (2009) 1.23
MYCN oncoprotein targets and their therapeutic potential. Cancer Lett (2010) 1.13
Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets (2010) 1.11
MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn (2010) 1.06
Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest (2004) 0.96
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Dev Biol (2011) 0.94
Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Differentiation (2010) 0.89